Earswitch to allow people with MND to communicate again using hidden, tiny ear muscle
(University of Bath) The 'Earswitch', being developed by a GP and a team of researchers at the University of Bath, could offer fresh hope for people with conditions such as Motor Neurone Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2021 Category: International Medicine & Public Health Source Type: news
Miniaturized models of neuron-muscle interactions give insight in ALS
(International Society for Stem Cell Research) Researchers have developed a new miniaturized model of neuromuscular junction formation that will have broad applications in studying motor neuron pathology and the discovery of potential therapeutics in ALS. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 22, 2021 Category: International Medicine & Public Health Source Type: news
Tipping Point: Woman has voice reconstructed thanks to ITV show appearance
Helen Whitelaw appeared on Tipping Point before Motor Neurone Disease rendered her speechless. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 15, 2021 Category: Consumer Health News Source Type: news
High cholesterol: The health condition has been linked to motor neurone disease
HIGH cholesterol may increase the likelihood of motor neurone disease - an incurable condition. Who is most at risk of developing the life-changing illness? And could statins protect against the malady? (Source: Daily Express - Health)
Source: Daily Express - Health - March 13, 2021 Category: Consumer Health News Source Type: news
Risdiplam Promising for Spinal Muscular Atrophy Risdiplam Promising for Spinal Muscular Atrophy
Infants with type 1 spinal muscular atrophy showed increased expression of functional survival motor neuron protein after 1 year of treatment in new FIREFISH findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 10, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Researchers reveal process behind harmful glial cell change in motor neurone disease
(The Francis Crick Institute) Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neurone disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi ™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease . SMA causes progressive muscle weakness and atrophy, and significant unmet need remains, particularly in adults livi...
Source: Roche Investor Update - February 26, 2021 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi ™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease . SMA causes progressive muscle weakness and atrophy, and significant unmet need remains, particularly in adults livi...
Source: Roche Media News - February 26, 2021 Category: Pharmaceuticals Source Type: news
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi ™ (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data show that treatment with Evrysdi at 12 months helped 90% (19/21) of these infants survive without permanent ventilation and 33% (7/21) sit withou t support for at least 5 seconds, which is not normally seen in the natural course of the disease. The study also found that treatment with Evrysdi increased the levels of survival of motor...
Source: Roche Investor Update - February 25, 2021 Category: Pharmaceuticals Source Type: news
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi ™ (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data show that treatment with Evrysdi at 12 months helped 90% (19/21) of these infants survive without permanent ventilation and 33% (7/21) sit withou t support for at least 5 seconds, which is not normally seen in the natural course of the disease. The study also found that treatment with Evrysdi increased the levels of survival of motor...
Source: Roche Media News - February 25, 2021 Category: Pharmaceuticals Source Type: news
Poor corticospinal motor neuron health is associated with increased symptom severity in the acute phase following repetitive mild TBI and predicts early ALS onset in genetically predisposed rodents - Alkaslasi MR, Cho NE, Dhillon NK, Shelest O, Haro-Lopez PS, Linaval NT, Ghoulian J, Yang AR, Vit JP, Avalos P, Ley EJ, Thomsen GM.
Traumatic brain injury (TBI) is a well-established risk factor for several neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, however, a link between TBI and amyotrophic lateral sclerosis (ALS) has not been clearly elucidate... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Motor neurone disease: Edinburgh scientists reveal breakthrough
University of Edinburgh scientists are a step closer to being able to reverse the damage caused by MND. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 19, 2021 Category: Consumer Health News Source Type: news
Rob Burrow: Rugby League legend's year living with MND
The Rugby League legend looks back on a year of challenges since his motor neurone disease diagnosis. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 25, 2020 Category: Consumer Health News Source Type: news
Antiepileptic drug reduces motor neuron excitability in ALS
(Massachusetts General Hospital) The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition, the multi-site study involves the first clinical investigation of ALS using a drug identified through an induced pluripotent stem cell model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2020 Category: International Medicine & Public Health Source Type: news
Motor Neurone Disease: Scientists find mutation that could end hell of disease
SCIENTISTS have identified a new genetic mutation that increases risk of motor neurone disease, raising hopes of better targeted treatments. (Source: Daily Express - Health)
Source: Daily Express - Health - December 2, 2020 Category: Consumer Health News Source Type: news
